Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady I Malik

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Journal of the American College of Cardiology|March 26, 2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF StudyJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac ContractilityAntonio Romero, Luke Ashcraft, Aroop Chandra, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
JAMA|July 19, 2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical TrialGregory D Lewis, Adriaan A Voors, Alain Cohen-Solal, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
Nature Cardiovascular Research|August 28, 2024
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathyJames J Hartman, Darren T Hwee, Julien Robert-Paganin, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Journal of the American College of Cardiology|March 26, 2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF StudyJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
European Journal of Heart Failure|March 2, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of Medicinal Chemistry|May 10, 2024
Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac ContractilityAntonio Romero, Luke Ashcraft, Aroop Chandra, et al.
Journal of the American College of Cardiology|February 2, 2018
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure CollaboratoryChristopher M O'Connor, Mitchell A Psotka, Mona Fiuzat, et al.
JAMA|July 19, 2022
Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical TrialGregory D Lewis, Adriaan A Voors, Alain Cohen-Solal, et al.
European Journal of Heart Failure|March 2, 2026
Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HFMisato Chimura, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|October 13, 2023
Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF TrialMaria Pabon, Jon Cunningham, Brian Claggett, et al.
Nature Cardiovascular Research|August 28, 2024
Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathyJames J Hartman, Darren T Hwee, Julien Robert-Paganin, et al.
The American Journal of Cardiology|April 19, 2026
Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract GradientsJosef Veselka, Ramon Gimeno, Theodore P Abraham, et al.
European Heart Journal|October 21, 2025
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialMartin S Maron, Juan Ramon Gimeno, Josef Veselka, et al.
Pageof 12